Literature DB >> 33728138

Ki67 Proliferation Index in Germinal and Non-Germinal Subtypes of Diffuse Large B-Cell Lymphoma.

Atif A Hashmi1, Syeda N Iftikhar1, Gul Nargus2, Omer Ahmed3, Ishaq Azeem Asghar4, Umme Aiman Shirazi1, Anoshia Afzal5, Muhammad Irfan6, Javaria Ali1.   

Abstract

Introduction Diffuse large B-cell lymphoma (DLBCL) is an aggressive B-cell lymphoma. The 2016 World Health Organization (WHO) update on hematopoietic tumors suggested that all DLBCL cases should be subtyped into germinal and non-germinal center phenotypes. Ki67 immunohistochemistry is a maker of cell proliferation and thus is used as a prognostic and predictive marker in various tumors of human body. Only a few studies evaluated the proliferative index of DLBCL subtypes in our population. Therefore, in this study, we evaluated the frequency of subtypes of DLBCL in our population and K67 index in each subtype. Methods A retrospective observational study was conducted in the Department of Histopathology, Liaquat National Hospital and Medical College, from January 2018 till December 2020, over a period of three years. A total of 101 cases with a histopathological diagnosis consistent DLBCL were included in the study. Immunohistochemical (IHC) stains CD10, B-cell lymphoma 6 (Bcl-6), and multiple myeloma oncogene 1 (MUM1) were applied for the further sub-categorization of DLBCL into germinal center B-cell-like (GCB) and non-GCB subtypes according to the Hans algorithm. The Ki67 index was interpreted in hot spots of the tumor and reported as an average percentage. Results Out of 101 DLBCL cases, 47.5% of DLBCL were GCB, while 52.5% were non-GCB subtypes. Bcl-2, Bcl-6, MUM1, c-Myc, CD10, and CD30 expression were noted in 62.4%, 45.5%, 42.6%, 44.6%, 39.6%, and 7.9% cases, respectively. The mean Ki67 index was 72.94±16.69%. The mean Ki67 index in non-GCB-type DLBCL was 77.67±14.80%, which was significantly higher than the mean Ki67 index in GCB-type DLBCL (67.70±17.22%) with a significant p-value (p=0.002). Cervical lymph node was the most common site of DLBCL, while the stomach was the most common extra-nodal site. A significant association of Ki67 index was noted with subtypes of DLBCL. A higher proportion of non-GCB-type DLBCL exhibited greater than 80% Ki67 index than GCB subtype DLBCL. Moreover, a significant association Ki67 index was noted with c-Myc positivity. A higher proportion of c-Myc-positive DLBCL had greater than 80% Ki67 index. Conclusion We found that non-GCB-type DLBCL had a higher Ki67 index than GCB subtype DLBCL, portending a poor prognostic significance of non-GCB subtype of DLBCL. Moreover, c-Myc expression was associated with a higher Ki67 index.
Copyright © 2021, Hashmi et al.

Entities:  

Keywords:  diffuse large b-cell lymphoma (dlbcl); germinal center b-cell-like (gcb); hans algorithm; ki67 index; proliferative index

Year:  2021        PMID: 33728138      PMCID: PMC7936471          DOI: 10.7759/cureus.13120

Source DB:  PubMed          Journal:  Cureus        ISSN: 2168-8184


  20 in total

1.  Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.

Authors:  Tina Marie Green; Ken H Young; Carlo Visco; Zijun Y Xu-Monette; Attilio Orazi; Ronald S Go; Ole Nielsen; Ole V Gadeberg; Torben Mourits-Andersen; Mikael Frederiksen; Lars Møller Pedersen; Michael Boe Møller
Journal:  J Clin Oncol       Date:  2012-06-04       Impact factor: 44.544

Review 2.  Lymphoma classification--from controversy to consensus: the R.E.A.L. and WHO Classification of lymphoid neoplasms.

Authors:  N L Harris; E S Jaffe; J Diebold; G Flandrin; H K Muller-Hermelink; J Vardiman
Journal:  Ann Oncol       Date:  2000       Impact factor: 32.976

3.  Ki67 is a Graded Rather than a Binary Marker of Proliferation versus Quiescence.

Authors:  Iain Miller; Mingwei Min; Chen Yang; Chengzhe Tian; Sara Gookin; Dylan Carter; Sabrina L Spencer
Journal:  Cell Rep       Date:  2018-07-31       Impact factor: 9.423

4.  Prognostic significance of MYC, BCL2, and BCL6 rearrangements in patients with diffuse large B-cell lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab.

Authors:  Nalan Akyurek; Aysegul Uner; Mustafa Benekli; Ibrahim Barista
Journal:  Cancer       Date:  2011-12-27       Impact factor: 6.860

5.  High Ki-67 expression in diffuse large B-cell lymphoma patients with non-germinal center subtype indicates limited survival benefit from R-CHOP therapy.

Authors:  Zhi-Ming Li; Jia-Jia Huang; Yi Xia; Ying-Jie Zhu; Wei Zhao; Wen-Xiao Wei; Wen-Qi Jiang; Tong-Yu Lin; Hui-Qiang Huang; Zhong-Zhen Guan
Journal:  Eur J Haematol       Date:  2012-03-27       Impact factor: 2.997

6.  Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.

Authors:  Nathalie A Johnson; Graham W Slack; Kerry J Savage; Joseph M Connors; Susana Ben-Neriah; Sanja Rogic; David W Scott; King L Tan; Christian Steidl; Laurie H Sehn; Wing C Chan; Javeed Iqbal; Paul N Meyer; Georg Lenz; George Wright; Lisa M Rimsza; Carlo Valentino; Patrick Brunhoeber; Thomas M Grogan; Rita M Braziel; James R Cook; Raymond R Tubbs; Dennis D Weisenburger; Elias Campo; Andreas Rosenwald; German Ott; Jan Delabie; Christina Holcroft; Elaine S Jaffe; Louis M Staudt; Randy D Gascoyne
Journal:  J Clin Oncol       Date:  2012-07-30       Impact factor: 44.544

7.  Ki-67 is a valuable prognostic predictor of lymphoma but its utility varies in lymphoma subtypes: evidence from a systematic meta-analysis.

Authors:  Xin He; Zhigang Chen; Tao Fu; Xueli Jin; Teng Yu; Yun Liang; Xiaoying Zhao; Liansheng Huang
Journal:  BMC Cancer       Date:  2014-03-05       Impact factor: 4.430

8.  Clinicopathological Features of Primary Neuroendocrine Tumors of Gastrointestinal/Pancreatobiliary Tract With Emphasis on High-Grade (Grade 3) Well-Differentiated Neuroendocrine Tumors.

Authors:  Atif A Hashmi; Javaria Ali; Syed Rafay Yaqeen; Omer Ahmed; Ishaq Azeem Asghar; Muhammad Irfan; Muhammad Ghani Asif; Muhammad M Edhi; Shumaila Hashmi
Journal:  Cureus       Date:  2021-01-11

9.  High Ki67 proliferation index but not cell-of-origin subtypes is associated with shorter overall survival in diffuse large B-cell lymphoma.

Authors:  Feras Zaiem; Rada Jerbi; Omar Albanyan; Jordyn Puccio; Zyad Kafri; Jay Yang; Ali M Gabali
Journal:  Avicenna J Med       Date:  2020-10-13

10.  Clinicopathological Spectrum of Primary and Metastatic Neuroendocrine Neoplasms.

Authors:  Atif A Hashmi; Javaria Ali; Kiran Khan; Omer Ahmed; Ata Ur Rehman; Muhammad Irfan; Saroona Haroon; Muhammad Ghani Asif
Journal:  Cureus       Date:  2020-11-29
View more
  2 in total

1.  Evaluation of Ki-67 as a Prognostic Marker in Diffuse Large B-Cell Lymphoma-A Single-Center Retrospective Cohort Study.

Authors:  Fabian Huber; Elisabeth Zwickl-Traxler; Martin Pecherstorfer; Josef Singer
Journal:  Curr Oncol       Date:  2021-11-08       Impact factor: 3.677

2.  Expression of PD-L1 and YWHAZ in Patients with Diffuse Large B Cell Lymphoma: A Possible Association with the Prognosis of Lymphoma.

Authors:  Shufang Yan; Qinyu Shang; Zhaopu Fan; Yuping Yang; Yanping Liu; Hongliang Gao; Ken Chen; Fei Liang; Xinxia Li; Qian Zhang; Huifang Yan
Journal:  J Immunol Res       Date:  2022-09-28       Impact factor: 4.493

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.